- Home
- LFT vs SKYE Comparison
LFT vs SKYE Comparison
Compare LFT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- SKYE
- Stock Information
- Founded
- LFT 2012
- SKYE 2012
- Country
- LFT United States
- SKYE United States
- Employees
- LFT N/A
- SKYE N/A
- Industry
- LFT Real Estate Investment Trusts
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- SKYE Health Care
- Exchange
- LFT Nasdaq
- SKYE Nasdaq
- Market Cap
- LFT 122.0M
- SKYE 108.5M
- IPO Year
- LFT N/A
- SKYE N/A
- Fundamental
- Price
- LFT $2.32
- SKYE $4.25
- Analyst Decision
- LFT Hold
- SKYE Buy
- Analyst Count
- LFT 2
- SKYE 7
- Target Price
- LFT N/A
- SKYE $15.50
- AVG Volume (30 Days)
- LFT 112.7K
- SKYE 294.2K
- Earning Date
- LFT 11-11-2025
- SKYE 11-06-2025
- Dividend Yield
- LFT 10.34%
- SKYE N/A
- EPS Growth
- LFT N/A
- SKYE N/A
- EPS
- LFT 0.18
- SKYE N/A
- Revenue
- LFT $25,803,999.00
- SKYE N/A
- Revenue This Year
- LFT $124.75
- SKYE N/A
- Revenue Next Year
- LFT N/A
- SKYE N/A
- P/E Ratio
- LFT $12.89
- SKYE N/A
- Revenue Growth
- LFT N/A
- SKYE N/A
- 52 Week Low
- LFT $2.05
- SKYE $1.14
- 52 Week High
- LFT $2.84
- SKYE $6.51
- Technical
- Relative Strength Index (RSI)
- LFT 56.45
- SKYE 66.34
- Support Level
- LFT $2.30
- SKYE $3.96
- Resistance Level
- LFT $2.37
- SKYE $4.35
- Average True Range (ATR)
- LFT 0.06
- SKYE 0.28
- MACD
- LFT 0.01
- SKYE 0.09
- Stochastic Oscillator
- LFT 82.81
- SKYE 91.15
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.